S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
Log in

scPharmaceuticals Stock Forecast, Price & News

+0.01 (+0.14 %)
(As of 03/8/2021 12:00 AM ET)
Today's Range
Now: $7.29
50-Day Range
MA: $6.99
52-Week Range
Now: $7.29
Volume68,562 shs
Average Volume102,301 shs
Market Capitalization$199.17 million
P/E RatioN/A
Dividend YieldN/A
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
scPharmaceuticals logo


Is SCPH A Good Stock To Buy Now? - Yahoo Finance
December 12, 2020 |  finance.yahoo.com
Is SCPH A Good Stock To Buy Now?
December 12, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SCPH
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$2.76 per share


Net Income$-33,000,000.00


Market Cap$199.17 million
Next Earnings Date3/23/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.31 out of 5 stars

Medical Sector

754th out of 1,971 stocks

Pharmaceutical Preparations Industry

361st out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
+0.01 (+0.14 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

scPharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

Is scPharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" scPharmaceuticals stock.
View analyst ratings for scPharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than scPharmaceuticals?

Wall Street analysts have given scPharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but scPharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is scPharmaceuticals' next earnings date?

scPharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for scPharmaceuticals

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) issued its earnings results on Monday, November, 16th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.05.
View scPharmaceuticals' earnings history

How has scPharmaceuticals' stock been impacted by COVID-19?

scPharmaceuticals' stock was trading at $7.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SCPH shares have decreased by 6.2% and is now trading at $7.29.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SCPH?

3 Wall Street analysts have issued 12 month price targets for scPharmaceuticals' shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate scPharmaceuticals' stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 69.2% from the stock's current price.
View analysts' price targets for scPharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are scPharmaceuticals' key executives?

scPharmaceuticals' management team includes the following people:
  • Mr. John H. Tucker, Pres, CEO, CFO & Director (Age 58, Pay $782.52k)
  • Ms. Rachael Nokes, Sr. VP of Fin. & Principal Accounting Officer (Age 46, Pay $390.66k)
  • Katherine Taudvin, Director of Corp. Devel. & Investor Relations
  • Dr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs
  • Mr. Michael D. Hassman, Sr. VP of Technical Operations

Who are some of scPharmaceuticals' key competitors?

What other stocks do shareholders of scPharmaceuticals own?

When did scPharmaceuticals IPO?

(SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is scPharmaceuticals' stock symbol?

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Ikarian Capital LLC (5.37%), Alyeska Investment Group L.P. (1.30%), Alyeska Investment Group L.P. (1.30%), BlackRock Inc. (1.18%), Renaissance Technologies LLC (0.90%) and Worth Venture Partners LLC (0.60%). Company insiders that own scPharmaceuticals stock include Andrew J Schwab, John H Tucker, Ra Capital Healthcare Fund Lp and Ra Capital Management, LP.
View institutional ownership trends for scPharmaceuticals

Which institutional investors are selling scPharmaceuticals stock?

SCPH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ikarian Capital LLC, Worth Venture Partners LLC, Northern Trust Corp, Alyeska Investment Group L.P., and Alyeska Investment Group L.P..
View insider buying and selling activity for scPharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying scPharmaceuticals stock?

SCPH stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Zacks Investment Management, Virtu Financial LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., Wells Fargo & Company MN, Dimensional Fund Advisors LP, and Dimensional Fund Advisors LP. Company insiders that have bought scPharmaceuticals stock in the last two years include Andrew J Schwab, John H Tucker, Ra Capital Healthcare Fund Lp, and Ra Capital Management, LP.
View insider buying and selling activity for scPharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of scPharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is scPharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $7.29.

How much money does scPharmaceuticals make?

scPharmaceuticals has a market capitalization of $199.17 million. The company earns $-33,000,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

How many employees does scPharmaceuticals have?

scPharmaceuticals employs 26 workers across the globe.

What is scPharmaceuticals' official website?

The official website for scPharmaceuticals is www.scpharma.com.

Where are scPharmaceuticals' headquarters?

scPharmaceuticals is headquartered at 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830.

How can I contact scPharmaceuticals?

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]

This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.